Definium Therapeutics, Inc. (DFTX) stock
DFTXNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
$32.08−0.92 (-2.79%)
Close on Nov 13, 2026Market cap $4.31BP/E –Yield –
Definium Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Definium Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $169.81M, up 60.3% year over year. For fiscal 2025 it was $117.67M, up 80.2% from the year before. The highest annual figure on record is $117.67M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $117.67M | +80.2% |
| FY2024 | Dec 31, 2024 | $65.30M | +25.3% |
| FY2023 | Dec 31, 2023 | $52.12M | +44.1% |
| FY2022 | Dec 31, 2022 | $36.17M | +4.0% |
| FY2021 | Dec 31, 2021 | $34.79M | +86.7% |
| FY2020 | Dec 31, 2020 | $18.63M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $46.14M | +48.9% |
| Q2 FY2026 | Jun 30, 2026 | $48.67M | +63.3% |
| Q1 FY2026 | Mar 31, 2026 | $41.48M | +77.6% |
| Q4 FY2025 | Dec 31, 2025 | $33.52M | +54.1% |
| Q3 FY2025 | Sep 30, 2025 | $30.98M | +80.2% |
| Q2 FY2025 | Jun 30, 2025 | $29.81M | +103.5% |
| Q1 FY2025 | Mar 31, 2025 | $23.36M | +99.5% |
| Q4 FY2024 | Dec 31, 2024 | $21.76M | +88.5% |
| Q3 FY2024 | Sep 30, 2024 | $17.19M | +30.2% |
| Q2 FY2024 | Jun 30, 2024 | $14.65M | -0.9% |
| Q1 FY2024 | Mar 31, 2024 | $11.71M | -7.1% |
| Q4 FY2023 | Dec 31, 2023 | $11.55M | +30.8% |
| Q3 FY2023 | Sep 30, 2023 | $13.20M | +69.9% |
| Q2 FY2023 | Jun 30, 2023 | $14.78M | +58.4% |
| Q1 FY2023 | Mar 31, 2023 | $12.60M | +23.0% |
| Q4 FY2022 | Dec 31, 2022 | $8.83M | -18.9% |
| Q3 FY2022 | Sep 30, 2022 | $7.77M | -13.8% |
| Q2 FY2022 | Jun 30, 2022 | $9.33M | +15.5% |
| Q1 FY2022 | Mar 31, 2022 | $10.24M | +50.3% |
| Q4 FY2021 | Dec 31, 2021 | $10.88M | – |
| Q3 FY2021 | Sep 30, 2021 | $9.02M | – |
| Q2 FY2021 | Jun 30, 2021 | $8.07M | – |
| Q1 FY2021 | Mar 31, 2021 | $6.81M | – |
See a number that looks wrong?